Luis Antonio Flores-López

Dr. Luis Antonio Flores-López

Laboratorio de Biomóleculas y Salud Infantil, Instituto Nacional de Pediatria, Mexico City, Ciudad de México, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Molecules
Verified
Journal Article
Open access
PDF file
SESergio Enriquez-Flores
Sergio Enriquez-Flores
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
ITItzhel Garcia Torres
Itzhel Garcia Torres
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
YMYoalli Martínez-Pérez
Yoalli Martínez-Pérez
Gabriel López-VelázquezGabriel López-Velázquez
Gabriel López-Velázquez
Cancer involves a series of diseases where cellular growth is not controlled. Cancer is a leading cause of death worldwide, and the burden of cancer incidence and mortality is rapidly growing, mainly in developing countries. Many drugs are currently used, from chemotherapeutic agents to immunotherapy, among others, along with organ transplantation. Treatments can cause severe side effects, including remission and progression of the disease with serious consequences. Increased glycolytic activity is characteristic of cancer cells. Triosephosphate isomerase is essential for net ATP production in the glycolytic pathway. Notably, some post-translational events have been described that occur in human triosephosphate isomerase in which functional and structural alterations are provoked. This is considered a window of opportunity, given the differences that may exist between cancer cells and their counterpart in normal cells concerning the glycolytic enzymes. Here, we provide elements that bring out the potential of triosephosphate isomerase, under post-translational modifications, to be considered an efficacious target for treating cancer.

15 July 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
SESergio Enriquez-Flores
Sergio Enriquez-Flores
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
ITItzhel Garcia Torres
Itzhel Garcia Torres
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
CNCabrera Nallely
Cabrera Nallely
Gabriel López-VelázquezGabriel López-Velázquez
Gabriel López-Velázquez
Therapeutic strategies for the treatment of any severe disease are based on the discovery and validation of druggable targets. The human genome encodes only 600–1500 targets for small-molecule drugs, but posttranslational modifications lead to a considerably larger druggable proteome. The spontaneous conversion of asparagine (Asn) residues to aspartic acid or isoaspartic acid is a frequent modification in proteins as part of the process called deamidation. Triosephosphate isomerase (TIM) is a glycolytic enzyme whose deamidation has been thoroughly studied, but the prospects of exploiting this phenomenon for drug design remain poorly understood. The purpose of this study is to demonstrate the properties of deamidated human TIM (HsTIM) as a selective molecular target. Using in silico prediction, in vitro analyses, and a bacterial model lacking the tim gene, this study analyzed the structural and functional differences between deamidated and nondeamidated HsTIM, which account for the efficacy of this protein as a druggable target. The highly increased permeability and loss of noncovalent interactions of deamidated TIM were found to play a central role in the process of selective enzyme inactivation and methylglyoxal production. This study elucidates the properties of deamidated HsTIM regarding its selective inhibition by thiol-reactive drugs and how these drugs can contribute to the development of cell-specific therapeutic strategies for a variety of diseases, such as COVID-19 and cancer.

25 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
ITItzhel Garcia Torres
Itzhel Garcia Torres
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
Gabriel López-VelázquezGabriel López-Velázquez
Gabriel López-Velázquez
Gloria Hernández-AlcántaraGloria Hernández-Alcántara
Gloria Hernández-Alcántara
SESergio Enriquez-Flores
Sergio Enriquez-Flores
Triosephosphate isomerase (TPI) dysfunction is a critical factor in diverse pathological conditions. Deficiencies in TPI lead to the accumulation of toxic methylglyoxal (MGO), which induces non-enzymatic post-translational modifications, thus compromising protein stability and leading to misfolding. This study investigates how specific TPI mutations (E104D, N16D, and C217K) affect the enzyme’s structural stability when exposed to its substrate glyceraldehyde 3-phosphate (G3P) and MGO. We employed circular dichroism, intrinsic fluorescence, native gel electrophoresis, and Western blotting to assess the structural alterations and aggregation propensity of these TPI mutants. Our findings indicate that these mutations markedly increase TPI’s susceptibility to MGO-induced damage, leading to accelerated loss of enzymatic activity and enhanced protein aggregation. Additionally, we observed the formation of MGO-induced adducts, such as argpyrimidine (ARGp), that contribute to enzyme inactivation and aggregation. Importantly, the application of MGO-scavenging molecules partially mitigated these deleterious effects, highlighting potential therapeutic strategies to counteract MGO-induced damage in TPI-related disorders.

29 January 2022 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
SESergio Enriquez-Flores
Sergio Enriquez-Flores
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
CNCabrera Nallely
Cabrera Nallely
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
ITItzhel Garcia Torres
Itzhel Garcia Torres

13 October 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
CMClaudia M. Malagón-Reyes
Claudia M. Malagón-Reyes
ITItzhel Garcia Torres
Itzhel Garcia Torres
YMYoalli Martínez-Pérez
Yoalli Martínez-Pérez
SESergio Enriquez-Flores
Sergio Enriquez-Flores
T-cell acute lymphoblastic leukemia (T-ALL) is a challenging childhood cancer to treat, with limited therapeutic options and high relapse rates. This study explores deamidated triosephosphate isomerase (dTPI) as a novel therapeutic target. We hypothesized that selectively inhibiting dTPI could reduce T-ALL cell viability without affecting normal T lymphocytes. Computational modeling and recombinant enzyme assays revealed that disulfiram (DS) and curcumin (CU) selectively bind and inhibit dTPI activity without affecting the non-deamidated enzyme. At the cellular level, treatment with DS and CU significantly reduced Jurkat T-ALL cell viability and endogenous TPI enzymatic activity, with no effect on normal T lymphocytes, whereas the combination of sodium dichloroacetate (DCA) with DS or CU showed synergistic effects. Furthermore, we demonstrated that dTPI was present and accumulated only in Jurkat cells, confirming our hypothesis. Finally, flow cytometry confirmed apoptosis in Jurkat cells after treatment with DS and CU or their combination with DCA. These findings strongly suggest that targeting dTPI represents a promising and selective target for T-ALL therapy.

Verified
Journal Article
Open access
PDF file
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
Ignacio De la Mora De la MoraIgnacio De la Mora De la Mora
Ignacio De la Mora De la Mora
ITItzhel Garcia Torres
Itzhel Garcia Torres
SESergio Enriquez-Flores
Sergio Enriquez-Flores
Luis Antonio Flores-LópezLuis Antonio Flores-López
Luis Antonio Flores-López
Gabriel López-VelázquezGabriel López-Velázquez
Gabriel López-Velázquez
Giardiasis represents a latent problem in public health due to the exceptionally pathogenic strategies of the parasite Giardia lamblia for evading the human immune system. Strains resistant to first-line drugs are also a challenge. Therefore, new antigiardial therapies are urgently needed. Here, we tested giardial arginine deiminase (GlADI) as a target against giardiasis. GlADI belongs to an essential pathway in Giardia for the synthesis of ATP, which is absent in humans. In silico docking with six thiol-reactive compounds was performed; four of which are approved drugs for humans. Recombinant GlADI was used in enzyme inhibition assays, and computational in silico predictions and spectroscopic studies were applied to follow the enzyme’s structural disturbance and identify possible effective drugs. Inhibition by modification of cysteines was corroborated using Ellman’s method. The efficacy of these drugs on parasite viability was assayed on Giardia trophozoites, along with the inhibition of the endogenous GlADI. The most potent drug against GlADI was assayed on Giardia encystment. The tested drugs inhibited the recombinant GlADI by modifying its cysteines and, potentially, by altering its 3D structure. Only rabeprazole and omeprazole decreased trophozoite survival by inhibiting endogenous GlADI, while rabeprazole also decreased the Giardia encystment rate. These findings demonstrate the potential of GlADI as a target against giardiasis.